BioRestorative Therapies, Inc. obtained approval from the FDA on August 6, 2025.
2 reports, 2 independent
Updated Aug 11
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BioRestorative Therapies, Inc. obtained approval from the FDA on August 6, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA approved therapeutics from a Cambridge-based company.1 source
BioRestorative Therapies, Inc. received FDA approval for its therapeutics.1 source
Keep exploring
The entities involved
Related events
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- FDA placed a clinical hold on the drug application submitted by Bright Minds Biosciences Inc.
- ADC Therapeutics received accelerated approval for its drug from the FDA.
- Adam Craig reported positive results that could support FDA approval for a treatment.
Coverage
Newest first; wire copies grouped- ZacksWhy This 1 Momentum Stock Could Be a Great Addition to Your Portfolio Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. While y
- GlobeNewswireBioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025 MELVILLE, N.Y., Aug. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (